The effects of a benzodiazepine receptor antagonist β-carboline ZK-93426 on scopolamine-induced impairment on attention, memory and psychomotor skills

Psychopharmacology

Volumn 123, Issue 4, 1996, Pages 361-373

  Duka, T ^a   Ott, H ^b   Rohloff, A ^b   Voet, B ^b  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

^b BAYER PHARMA AG   (Germany)

Author keywords

Attention; Memory; Psychomotor activity; Scopolamine; Vigilance; Carbolines

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; 5 ISOPROPOXY 4 METHYL BETA CARBOLINE 3 CARBOXYLIC ACID ETHYL ESTER; BENZODIAZEPINE RECEPTOR; BENZODIAZEPINE RECEPTOR BLOCKING AGENT; BENZODIAZEPINE RECEPTOR INVERSE STIMULATING AGENT; BETA CARBOLINE DERIVATIVE; PLACEBO; SCOPOLAMINE;

ADULT; ALERTNESS; ARTICLE; ATTENTION; CHOLINERGIC SYSTEM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; ELECTROENCEPHALOGRAM; HUMAN; HUMAN EXPERIMENT; INFORMATION PROCESSING; INTRAVENOUS DRUG ADMINISTRATION; LEARNING DISORDER; LOGIC; MEMORY; NORMAL HUMAN; PRIORITY JOURNAL; PSYCHOMETRY; PSYCHOMOTOR PERFORMANCE; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; TASK PERFORMANCE; VIDEORECORDING; VOLUNTEER; WORD RECOGNITION; WORKING MEMORY;

ADULT; AROUSAL; ATTENTION; CARBOLINES; COGNITION; DOUBLE-BLIND METHOD; ELECTROENCEPHALOGRAPHY; GABA ANTAGONISTS; GABA MODULATORS; HUMANS; LORAZEPAM; MEMORY; MENTAL PROCESSES; PARASYMPATHOLYTICS; PSYCHOMOTOR PERFORMANCE; RECEPTORS, GABA-A; SCOPOLAMINE;

EID: 0029919662     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02246647     Document Type: Article

References (57)

1. Aarsland D, Larsen JP, Reinvang I, Aasland AM (1994) Effects of cholinergic blockade on language in healthy young women implications for the cholinergic hypothesis in dementia of the Alzheimer type. Brain 117:377-1384
2. Arnold W (1970) Der Pauli Test. Anweisung Zur Sachgemäße Durchführung. Auswertung Und Anwendung Des Kraepelinschen Arbeitsversuches. J A Bath Verlag, München
3. Baddeley (1968) A 3 min reasoning test based on grammatical transformation. Psychon Sci 10: 341-342
4. Beatty WW, Butters N, Janowsky DS (1986) Patterns of memory failure after scopolamine treatment: implications for cholinergic hypotheses of dementia. Behav Neural Biol 45:196-211
5. Blin J, Piercey MF, Giuffra ME, Mouradian MM, Chase TN (1994) Metabolic effects of scopolamine and physostigmine in human brain measured by positron emission tomography. J Neurol Sci 123:44-51
6. Bowen DM, Francis PT, Chessel IP, Webster Mt (1994) Neurotransmission the link integrating Alzheimer research? Trends Neurosci 17:149-150
7. Brass EP, Polinsky R, Sramek JJ, Moore M, Jones D, Veroff AE, Wardle TS, Cutler NR (1995) Effects of the cholinomimetic Sdz Ens-163 on scopolamine-induced cognitive impairment in humans. J Clin Psychopharmacol 15:58-62
8. Brioni JD (1993) Role of GABA during the multiple consolidation of memory. Drug Dev Res 28:3-27
9. Brown MW, Brown J, Bowes JB (1989) Absence of priming coupled with substantially preserved recognition in lorazepam-induced amnesia. Q J Exp Psychol 41a:599-617
10. Buschke H, Altman Fuld P (1974) Evaluating storage, retention and retrieval in disordered memory and learning. Neurology 24:1019-1025
11. Caine ED, Weingartner H, Ludlow CL, Cudahy EA, Wehry S (1981) Qualitative analysis of scopolamine induced amnesia. Psychopharmacology 74:74-80
12. Callaway E (1984) Human information processing: some effects of methylphenate, age and scopolamine. Biol Psychiatry 19: 649-666
13. Cole BJ, Jones GH (1995) Double dissociation between the effects of muscarinic antagonists and benzodiazepine receptor agonists on the acquisition and retention of passive-avoidance. Psychopharmacology 118:37-41
14. Curran HV, Schifano F, Lader M (1991) Models of memory dysfunction? A comparison of the effects of scopolamine and lorazepam on Memory, psychomotor performance and mood. Psychopharmacology 100:463-471
15. Deutsch JA (1971) The cholinergic synapse and the site of memory. Science 174:788-794
16. Dorow R, Horowski R, Paschelke G, Amin M, Braestrup C (1983) Severe anxiety induced by Fg 7142, a β-carboline ligand for benzodiazepine receptors. Lancet 2:98
17. Dorow R, Berenberg D, Duka T, Sauerbrey N (1987) Amnestic effects of lormetazepam and their reversal by the benzodiazepine antagonist Ro 15-1788. Psychopharmacology 93:507-514
18. Drachman DA, Leavitt J (1974) Human memory and the cholinergic system. Arch Neurol 30:113-121
19. Drachman DA, Sahakian BJ (1979) Effects of cholinergic agents on human learning and memory. In: Barbeau A, Crowdon JH, Wurtman RJ (eds) New York, Nutrition and the brain. Raven Press, pp 351-366
20. Duka T (1991) Bidirectional activity of benzodiazepine receptor ligands in cognitive functions in humans, in: Briley M, File SE (eds) New concepts in anxiety. Macmillan London, pp 440-458
21. Duka T, Dorow R (1995) Human experimental psychopharmacology of benzodiazepine receptor inverse agonists and antagonists. In Sarter M, Nutt DJ (eds) Inverse agonists at benzodiazepine receptors. Wiley, New York, pp 243-270
22. Duka T, Stephens DN, Krause W, Dorow R (1987) Humans studies on the benzodiazepine receptor antagonist β-carboline Zk 93 426:preliminary observations on psychotropic activity. Psychopharmacology 93:421-427
23. Duka T, Edelmann V, Schutt B, Dorow R (1988a) β-Carbolines as tools in memory research. Human data with the β-carboline ZK 93 426. In: Hindmarch I, Ott H, Roth T (eds) Benzodiazepine receptor ligands, memory and information processing. Psychopharmacology Suppl. 6. Springer, New York, pp 246-261
24. Duka T, Goerke D., Dorow R, Höller L, Fichte K (1988b) Human studies on the benzodiazepine receptor antagonist β-carboline Zk 93 426: antagonism of lormetazepam's psychotropic effects. Psychopharmacology 95:463-472
25. Duka T, Stephens DN, Dorow R (1990) Cognitive enhancing properties of antagonist β-carbolines: new insights into clinical research on the treatment of dementias? In: Maurer K, Riederer P, Beckmann H (eds) Alzheimer's disease epidemiology, neuropathology, neurochemistry clinics. Springer, Wien, pp 55-564
26. Duka T, Edelmann V, Dorow R, Fichte K (1992) Scopolamine induced amnesia in humans: lack of effects of the benzodiazepine receptor antagonist β-carboline Zk 93 426. J Psychopharmacol 6:382-388
27. Duka T, Redemann B, Voet B (1995) Scopolamine and lorazepam exert different patterns of effects in a test battery assessing stages of information processing. Psychopharmacology 119: 315-324
28. Frith CD, Richardson JTE, Samuel M, Crow TJ, Mc Kenna PJ (1984) The effects of intravenous diazepam and hyoscine upon human memory. Q J Exp Psychol 36a: 133-144
29. Ghoneim MM, Mewald SP (1975) Effects of diazepam and scopolamine on storage, retrieval and organizational processes in memory. Psychopharmacologica 44:257-262
30. Ghoneim MM, Mewald SP (1977) Studies on human memory: the interactions of diazepam, scopolamine and physostigmine. Psychopharmacology 52:1-6
31. Imperato A, Dazzi L, Obinu MC, Gessa GL, Biggio G (1993) Inhibition of hippocampal acetylcholine-rel by benzodiazepines - antagonism by fllumazenil. Eur J Pharmacol 238:135-137
32. Kopelman MD (1987) How far could cholinergic depletion account for the memory deficits of Alzheimer-type dementia or the alcoholic Korsakoff syndrome? In: Stahl SM, Iversen SD, Goodman EC (eds) Cognitive neurochemistry Eds Oxford University Press, Oxford, pp 303-327
33. Lines CR, Ambrose JH, Heald A, Traub M (1993) A double-blind, placebo-controlled study of the effects of eptastigmine on scopolamine-induced cognitive deficits in healthy male-subjects. Human psychopharmacol Clin Exp 8:271-278
34. Litvan I, Sirigu A, Toothman J, Grafman A (1995) What can preservation of autobiographical memory after muscarinic blockade tell us about the scopolamine model of dementia. Neurology 45:387-389
35. Mauri M, Sinforiani E, Reverberi F, Merlo P, Bono G (1994) Pramiracetam effects on scopolamine-induced amnesia in healthy volunteers. Arch Gerontol Geriatr 18:133-139
36. Molchan SE, Matochik JA, Zametkin AJ, Szymanski HV, Cantillon M, Cohen RM, Sunderland T (1994) A double FDG Pet study of the effects of scopolamine in older adults. Neuropsycho-pharmacology. 10[3]:191-198
37. Ott H, Mcdonald RJ, Fichte K, Hermann WM (1982) Interpretation of correlation between EEG power spectra and psychological performance variables within the concepts of "subvigilance", "attention" and "psychomotoric impulsion". In: Hermann VM (ed) EEG In Drug Research. Gustav Fischer, Stuttgart New York, pp 227-247
38. Ott H, Rohloff A, Aufdembrinke B, Fichte K (1988) Anterograde and retrograde amnesia after lormetazepam and flunitrazepam. In: Hindmarch I, Ott H (eds) Benzodiazepine receptor ligands. memory and information processing. Psychopharmacology Series 6, Springer, New York, pp 180-194
39. Preda L, Alberoni M, Bressi S, Cattanco C, Parini J, Canal N, Franceschi M (1993) Effects of acute doses of oxiracetam in the scopolamine model of human amnesia. Psychopharmacology 110:421-426
40. Randt CT, Brown ER, Osborne DP (1980) A memory test for longitudinal measurement of mild to moderate deficits. Clin Neuropsychol II 4:20-32
41. Richardson JTE, Frith CD, Scott E, Crow T, Cunningham-Owens D (1984) The effects of intravenous diazepam and hyoscine upon recognition memory. Behav Brain Res 14:193-199
42. Rusted JM (1994) Cholinergic blockade and human information processing: are we asking the right questions? J Psychopharmacol 8:54-59
43. Rusted JM, Warburton DM (1988) The effects of scopolamine on working memory in healthy young volunteers Psychopharmacology 96:145-152
44. Rusted JM, Warburton DM (1989) Effects of scopolamine on verbal memory; a retrieval or acquisition deficit? Neuropsychobiology 21:76-83
45. Rusted JM, Eaton -Williams P, Warburton DM (1991) A comparison of the effects of scopolamine and diazepam on working memory Psychopharmacology 105:442-445
46. Sahakian BJ (1988) Cholinergic drugs and human cognitive performance. In: Iversen Ll, Iversen SD, Snyder SH (eds) Handbook of psychopharmacology Vol. 20. Plenum Press, London, pp 393-424
47. Sahakian BJ, Coull JT (1994) Nicotine and tetrahydroaminoacradine evidence for improved attention in patients with dementia of the Alzheimer type. Drug Dev Res 31:80-88
48. Safer DJ, Allen RP (1971) The central effects of scopolamine in man. Biol Psychiatry 3:347-355
49. Sarter M, Schneider HH, Stephens DN (1988) Treatment strategies for senile dementia: antagonist β-carbolines. Trends Neurosci 11:13-17
50. Siegfried K (1995) The efficacy of cholinergic drugs in patients with Alzheimer's disease. Focus on the aminoacridines. Hum psychopharmacol clin Exp 10:89-96
51. Sutherland T, Tariot PN, Cohen RM, Weingartner H, Mueller EA, Murphy DI (1987) Anticholinergic sensitivity in patients with dementia of the Azheimer type and age matched controls: a dose response study. Arch Gen Psychiatry 44:418-426
52. Tiplady B (1985) An automated test battery for the detection of changes in mental function and psychomotor performance. Br J Clin Pharmacol 20:305p
53. Tiplady B (1992) Continuous attention: rationale and discriminant validation of a test designed for use in psychopharmacology. Behav Res Methods Instr Comput 24:16-21
54. Warburton DM, Rusted JM (1993) Cholinergic control of cognitive resources. Neuropsychobiology 28:43-46
55. Weingartuer HJ (1985) Models of memory dysfunctions. Ann NY Acad Sci 444: 359-369
56. Weingartner HJ, Hommer D, Lister RG, Thompson K, Wolkowitz O (1992) Selective effects of triazolam on memory. Psychopharmacology 106: 341-345
57. Wesnes K, Warburton DM (1984) Effects of scopolamine and nicotine on human rapid information processing performance. Psychopharmacology 82:147-150